LAKE ZURICH — Fresenius Kabi mentioned it has been granted an expanded use of a dietary drug, which the Food and Drug Administration says can now be prescribed for infants.
“The FDA approval of SMOFlipid for pediatric sufferers represents an vital enlargement of our parenteral diet portfolio and our continued dedication to offering revolutionary diet merchandise to our medical companions and the sufferers they serve,” mentioned Gordon Sacks, senior director Medical Affairs, Fresenius Kabi USA.
Parenteral diet is the intravenous administration of amino acids (protein), carbohydrates (dextrose), lipids (fat), electrolytes, nutritional vitamins and different hint components for sufferers who can not digest or take up enough diet through the gastrointestinal tract. It could be offered within the hospital, in long-term care services, or at residence.
https://www.dailyherald.com/business/20220325/fresenius-kabi-nutrition-drug-approved-for-babies
